|
Q3 FY2026
As of Jun 30, 2026
|
Q2 FY2026
As of Mar 31, 2026
|
Q1 FY2026
As of Dec 31, 2025
|
Q4 FY2025
As of Sep 30, 2025
|
Q3 FY2025
As of Jun 30, 2025
|
Q2 FY2025
As of Mar 31, 2025
|
Q1 FY2025
As of Dec 31, 2024
|
Q4 FY2024
As of Sep 30, 2024
|
Q3 FY2024
As of Jun 30, 2024
|
Q2 FY2024
As of Mar 31, 2024
|
Q1 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Sep 30, 2023
|
Q3 FY2023
As of Jun 30, 2023
|
Q2 FY2023
As of Mar 31, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 30, 2022
|
Q3 FY2022
As of Jun 30, 2022
|
Q2 FY2022
As of Mar 31, 2022
|
Q1 FY2022
As of Dec 31, 2021
|
Q4 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Incentive and tax receivables | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities - Note 3 | ||||||||||||||||||||
| Deferred grant income - Note 4 | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| 10,000,000 preferred stock, par value $0.001 per share | ||||||||||||||||||||
| 92,696,842 common shares (September 30, 2025 - 86,668,521) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Share proceeds receivable | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders’ Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Equity | ||||||||||||||||||||
Loading...
